Technology advancements in synthesis and modification of nanoscale materials have advanced the development of different medical applications. Nanoparticles (NPs) have demonstrated promising potentials in diagnostic medicine especially for magnetic resonance imaging (MRI). Iron oxide, gold, and gadolinium NPs have been used in preclinical and clinical studies as contrast enhancing agents. Studies are ongoing to find the optimum parameters of these NPs as contrast agents (CAs) of MRI. This study aims to review the recent applications of iron oxide, gold, and gadolinium NPs as contrast enhancing agents in MRI for diagnosis of different disorders. The databases of PubMed (1980PubMed ( -2016, Web of Science (1980Science ( -2016, Scopus (1980), and Google Scholar (1980 were explored using the search terms "Nanoparticles," "Contrast agents," "Magnetic Resonance Imaging" and "disease." The obtained results were screened for the title and abstract and comprehensively reviewed. MRI CAs are divided into T1 and T2 CAs, respectively, used for T1 and T2 weighted protocols in MRI. Iron oxide, gadolinium, and gold NPs are the most common CAs used in MRI. High magnetization values, small size, narrow particle size distribution are the main features of NPs as CAs in MRI. Gadolinium is the most common T1 CAs used in MRI. However, it is associated with toxicity which is a serious concern in patients with renal failure. Iron oxide NPs can be used for these patients. However, the main limitation of iron oxide NPs is limited relaxivity. The relaxivity strongly depends on the size of NP. Paramagnetic NPs serve as T1 CAs and super paramagnetic NPs as T2 CAs. Modulating the size of NPs is the main parameter to adjust different NPs for different MRI protocols. Recent years to overcome the problem of gadolinium and iron oxide NPs, different paramagnetic and super paramagnetic NPs are developed.
INTRODUCTION
N oninvasive assessment and imaging of internal organs of a human body has been always a main challenge to physicians and researchers. [1] Magnetic resonance imaging (MRI) is the most common diagnostic imaging modality in clinical medicine due to its excellent spatial resolution, noninvasive and nondestructive nature. [2] MRI is imaging of soft tissue and in some cases cannot generate a sufficient contrast. The development of MRI to one of the most powerful techniques in clinical diagnosis is accompanied by the progress in the design of contrast agents (CAs), which enhance image quality. [3] MR images frequently rely on the differences in tissue relaxation times, both longitudinal (T1) and transverse (T2), to generate image contrast. [4] After protons are excited with a radiofrequency (RF) pulse applied perpendicular to the magnetic field, the protons will realign themselves with the magnetic field, a process referred to as relaxation. MRI signals are modulated by the rates at which protons return to equilibrium after an RF pulse. The difference in T1 and T2 relaxation times allow differentiation between soft tissues, bone, air, and liquids in the body. [5] Disease detection with MRI is often difficult because areas involved in the disease have similar signal intensity compared to the surrounding healthy tissue; therefore, requiring signal enhancement using CAs. [6] CAs interact with water molecules, leading to altered proton T1 or T2 relaxation times. [7] Contrast in MRI is most often defined by "T1" (spin-spin) or "T2" (spin-lattice) relaxation times, depending on the exact pulse sequence used to excite and then measure the relaxing spins. Exogenous CAs may be employed to alter local T1 or T2 relaxation times to produce highly enhanced tissue contrast as compared with the expected background T1 or T2 signals. [8] Nanotechnology has revolutionized the potentials of the MRI imaging modality. Nanoparticles (NPs) continue to receive attention in the field of medical imaging for their potential as specific CAs in vitro and in vivo. [9] [10] [11] The combination of multimodal imaging and theranostics will lead to cuttingedge technologies in which the potential of the NPs can be maximized. [12] However, the sensitivity at cellular/molecular imaging level is obviously lower than positron emission tomography and fluorescence imaging. MRI CAs, such as superparamagnetic iron oxide NPs (SPIONs), are emerging as one of the most promising probes for improving contrast at cellular or even molecular levels. [13] [14] [15] [16] [17] [18] [19] The use of CAs in MRI facilitates a more accurate diagnosis by enhancing the contrast between tissues. Recently, CAs have also been combined with target-directing molecules to visualize specific tissues and molecules. [20, 21] In this regard, SPIONs, which induce the dark contrast enhancement in T2-weighted MR images, have been commercialized as T2 CAs. [16, [22] [23] [24] [25] [26] [27] In this paper, we will review the characteristics of different types of NPs including iron oxide, gold, and gadolinium which have been developed as contrast enhancing agents in MRI. Characteristics such as size, clinical applications, protein/ligand, relaxivity, and toxicity for each type of NPs are discussed.
METHOD
The databases of PubMed, Web of Science, and Google Scholar were searched from the first data available to 2016. The following key words were used "MRI" and "CA" and "NP." The obtained records were reviewed for the title and abstract by two authors independently. Then, a consensus decision was made whether the studies are relevant for the review topic. Human and animal studies including the use of NPs the NPs used in MRI. Limited number of studies in this field and heterogeneity in the design and methodology of the studies, we aimed to provide a comprehensive and descriptive overview of all aspect of applications of NPs for more accurate diagnostic MRI.
Search method
The scientific records were retrieved by a systematic search of multiple bibliographic databases and the last update of the search was performed on to December 10 th 2016 including PubMed (1980 PubMed ( -2016 , Web of Science , Scopus (1980 Scopus ( -2016 , and Google Scholar . The language of the search was limited to English. The search key words based on the MeSH heading included "MRI" and "CA" and "NPs." The titles and abstracts of all the records retrieved by the search strategy were reviewed by two authors (AY and HM) and the relevant papers with full texts available were used for further assessments. Moreover, the reference lists of the relevant papers were checked manually to identify additional eligible studies. These papers also were included for the full review.
Inclusion and exclusion criteria
The identification and screening of the titles for inclusion or exclusion were performed independently by the two reviewers (AY and HM) and disagreements were resolved by discussion. Only original articles were eligible if they provided the following characteristics: (1) Human and animal studies that used of NPs in MRI, (2) in vivo and in vitro studies, (3) articles that evaluated diagnosis variety of cancers and tumors using NPs. Studies were excluded if: (a) abstract only, (b) review or meta-analysis, (c) books, (d) letters, (e) conference documents, (f) case reports, (g) editorial, (h) guideline, and (i) pilot study. The flowchart of the study process is depicted in Figure 1 .
RESULTS

Characteristics of studies
A total of 508 records were retrieved in the searching process. Studies were excluded if abstract only, review or metaanalysis, books, letters, conference documents, case reports, editorial, guideline, and pilot study. Finally, 17 articles fulfilled the criteria to be included in the final reviewing. NPs should be biocompatible, nontoxic, and stable for in vivo applications. These features can be controlled by changing the size and the coating's properties of NPs. [13, 28] MRI CAs are divided into T1 and T2 CAs, respectively, used for T1 and T2 weighted protocols in MRI. Iron oxide, gadolinium, and gold NPs (AuNPs) are the most common CAs used in MRI. High magnetization values, small size, narrow particle size distribution are the main features of NPs as CAs in MRI. Gadolinium is the most common T1 CAs used in MRI. However, it is associated with toxicity which is a serious concern in patients with renal failure. Iron oxide NPs can be used for these patients. However, the main limitation of iron oxide NPs is limited relaxivity. The relaxivity strongly depends on the size of NP. Paramagnetic
NPs serve as T1 CAs and super paramagnetic NPs as T2 CAs.
SPIONs
Iron oxide NPs are iron oxide particles with diameters between 1 and 100 nm. 
Gadolinium NPs
Gadolinium (Gd 3+ ) ion is the most commonly used metal ion as CA in MRI. The main characteristic of Gd 3+ ion is the presence of seven unpaired electrons combined with a long electron spin relaxation time that makes this metal a very efficient relaxation enhancing agent. [34, 35] The five MRI CAs approved by the FDA are based on the Gd 3+ ion, the material has high ability to catalyze the relaxation of the water signal and create positive contrast in MRI. [3] Several methods are known for the synthesis of gadolinium oxide NPs, mostly based on precipitation of the hydroxide by the reaction of gadolinium ions with hydroxide, followed by thermal dehydration to the oxide. The NPs are always coated with a protective material to avoid the formation of larger polycrystalline aggregates. [3, 4, 7, 33, [36] [37] [38] Gadolinium oxide NPs are potential CAs for MRI. Sizes of these NPs are <65 nm. Gadolinium oxide NPs have a relaxivity of <20/s/ mM. The main clinical challenge of using gadolinium NPs is high toxicity of these agents. Gadolinium is very toxic in ionic form (Gd 3+ ion) which extremely interferes with calcium channels and protein binding sites so that cannot be administered directly. [19, [39] [40] [41] [42] [43] [44] Free Gd ions accumulate in the liver, spleen, kidney, and bones. To reduce the side effects of toxic ions and prevent tissue interaction, Gd 3+ ions are combined with chelating ligands. However, toxic Gd 3+ ions may still be released from some chelates via transmetallation with other metal ions such as Zn 2+ , Ca 2+ , and Cu 2+ inside the 
